Neuland Laboratories
Neuland Laboratories Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Neuland Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Neuland Laboratories Ltd trades at a P/E of 60.67× and P/B of 11.77×.
Valuation
Profitability
Growth
Financial Health
Neuland Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Neuland Laboratories Ltd, switchable between annual and quarterly views, consolidated or standalone.
Neuland Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹22,067.41 Cr and reported EPS of ₹283.45.
| Period | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 |
| Other Income | 3 | 4 | 16 | 2 | 10 | 13 | 21 | 30 |
| Total Income | 670 | 767 | 953 | 953 | 1,201 | 1,571 | 1,497 | 2,053 |
| Cost of Goods Sold (COGS) | 366 | 380 | 438 | 422 | 478 | 577 | 588 | 756 |
| Gross Profit | 301 | 383 | 499 | 529 | 713 | 981 | 889 | 1,267 |
| +Operating Expenses | 242 | 281 | 352 | 386 | 441 | 519 | 566 | 693 |
| EBITDA | 58 | 102 | 147 | 143 | 272 | 463 | 323 | 574 |
| +Non-Operating Expenses | 42 | 53 | 58 | 63 | 66 | 74 | 150 | 116 |
| Profit Before Tax (PBT) | 20 | 53 | 105 | 82 | 216 | 401 | 346 | 489 |
| +Tax Expense | 4 | 37 | 25 | 18 | 52 | 101 | 86 | 125 |
| Profit After Tax (PAT) | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 364 |
| Earnings Per Share (EPS) | 12.82 | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 283.71 |
| Diluted Shares Outstanding (Nos.) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| +Additional Disclosures | 1,017 | 1,093 | 1,285 | 1,287 | 1,460 | 1,748 | 1,815 | 2,321 |
| Sales Growth % | — | 14.38 | 22.84 | 1.51 | 25.25 | 30.84 | -5.24 | 36.98 |
| YoY Sales Growth % | — | 14.38 | 22.84 | 1.51 | 25.25 | 30.84 | -5.24 | 36.98 |
| Material Cost % | 54 | 51 | 47 | 46 | 41 | 41 | 39 | 41 |
| Employee Cost % | 17 | 16 | 16 | 19 | 17 | 16 | 18 | 17 |
| Other Cost % | 20 | 21 | 22 | 21 | 20 | 17 | 20 | 17 |
| OPM % | 9 | 13 | 16 | 15 | 23 | 30 | 22 | 28 |
| Tax % | 19 | 69 | 23 | 22 | 24 | 25 | 25 | 26 |
| Profit Growth % | — | -1.41 | 397.40 | -20.85 | 156.21 | 83.51 | -13.32 | 39.94 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 33 | 71 | 107 | 94 | 219 | 403 | 258 | 483 |
Neuland Laboratories segment analysis: revenue and profit mix.
Disclosed business segments at Neuland Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Neuland Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Neuland Laboratories Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Neuland Laboratories Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Neuland Laboratories Ltd's investment case rests on 7 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong Returns. ROE of 14.8% and ROCE of 18.7% indicate efficient capital utilization and strong operational efficiency, reflecting the company's ability to generate profits from shareholder funds and overall capital.
Healthy Operating Margin. An Operating Profit Margin (OPM) of 17.6% suggests robust core business profitability and effective cost management, which is crucial for sustained financial health and competitive advantage.
Low Debt-to-Equity. A very low debt-to-equity ratio of 0.10 highlights a conservative financial structure, significantly reducing financial risk and providing flexibility for future investments or economic downturns.
Significant Promoter Holding. Promoters hold a substantial 32.6% stake, indicating strong management commitment and alignment with shareholder interests, fostering confidence in the company's long-term strategic direction.
Institutional investor confidence is evident with FII holdings rising from 17.39% in June 2022 to 20.60% by September 2025, alongside DII holdings increasing from 6.45% to 13.55% in the same period.
What can break it.
High P/E Ratio. The company's high P/E ratio of 150.00 suggests a premium valuation compared to its earnings, potentially indicating overvaluation and increasing the risk of future price corrections for investors.
Sharp Quarterly Profit Decline. A significant 83.1% decline in recent quarterly profit raises serious concerns about earnings stability and sustainability, requiring close monitoring of underlying operational challenges.
Substantial Stock Volatility. The stock has shown significant volatility, trading between a high of ₹18100 and a low of ₹10060, exposing investors to considerable price risk and demanding a higher risk tolerance.
Declining Promoter Holdings. Promoter holdings have decreased from 36.22% in June 2022 to 32.64% by September 2025, which could signal a lack of confidence or strategic shifts, warranting further investigation.
Quarterly Sales Contraction. A notable 33.4% decline in quarterly sales indicates potential demand weakness or competitive pressures, impacting revenue growth and overall market position.
What would change my mind.
Trim if P/E re-rates above 79. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 16.57. Balance sheet risk re-prices growth multiples fast.
Income thesis breaks if the dividend is cut or yield falls below 0.10%.
Neuland Laboratories Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Neuland Laboratories Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Neuland Laboratories Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Neuland Laboratories Ltd — derived from the live tape, not yesterday's close.
Neuland Laboratories Ltd last traded at ₹17,198 with an intraday range of ₹16,981–₹17,400 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹17198.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 18243.00 | +1045.00 | +6.08% |
| R3 | 17824.00 | +626.00 | +3.64% |
| R2 | 17612.00 | +414.00 | +2.41% |
| R1 | 17405.00 | +207.00 | +1.20% |
| PIVOT | 17193.00 | -5.00 | -0.03% |
| CURRENT | 17198.00 | — | — |
| S1 | 16148.00 | -1050.00 | -6.11% |
| S2 | 16567.00 | -631.00 | -3.67% |
| S3 | 16774.00 | -424.00 | -2.47% |
| S4 | 16986.00 | -212.00 | -1.23% |
NEULANDLAB is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 17100 ~ 17307
Trading Inside opening range
Neuland Laboratories Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Neuland Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Neuland Laboratories Ltd stood at 47.6% of traded volume, against a 20-day average of 42.1%.
Neuland Laboratories announcements: results, concalls, ratings, M&A.
Filings Neuland Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Neuland Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 145 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Intimation about Schedule of Analyst / Institutional Investor Meeting on June 11, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Intimation about Schedule of Analyst / Institutional Investor Meeting on June 8 & 9, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Neuland Laboratories Limited has informed the Exchange about Schedule of meet on May 28, 2026
Analysts/Institutional Investor Meet/Con. Call Updates
Transcript of the Earnings Call conducted on May 12, 2026
Copy of Newspaper Publication
Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Neuland Laboratories insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Neuland Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.
Neuland Laboratories insider activity below tracks 10 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 25 Mar 2026 | buy | +96.0 K | ₹116.12 Cr | ₹12,096.00 |
| Davuluri Saharsh Rao | Insider | 04 Mar 2026 | buy | +12.5 K | — | — |
| Deepthi Davuluri | Insider | 04 Mar 2026 | buy | +12.5 K | — | — |
| Davuluri Ownership Trust | Insider | 28 Feb 2025 | buy | +79.5 K | — | — |
| Saharsh Rao Davuluri | Insider | 28 Feb 2025 | sell | −79.5 K | — | — |
| Sucheth Rao Davuluri | Insider | 25 Feb 2025 | sell | −79.6 K | — | — |
| Davuluri Ownership Trust | Insider | 25 Feb 2025 | buy | +32.54 L | — | — |
| Davuluri Vijaya Rao | Insider | 24 Feb 2025 | sell | −6.08 L | — | — |
| Davuluri Ramamohan Rao | Insider | 24 Feb 2025 | sell | −25.66 L | — | — |
Neuland Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Neuland Laboratories has declared, sequenced by announce and record date.
Neuland Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Neuland Laboratories Ltd: business, sector, key facts.
What Neuland Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Neuland Laboratories Ltd operates in the Healthcare, listed as NSE: NEULANDLAB, BSE: 524558.
Neuland Laboratories Limited is a global manufacturer and supplier of active pharmaceutical ingredients (APIs). Its primary business centers around the production and distribution of these essential components used in the creation of pharmaceutical drugs. The company serves a broad international market, with operations spanning India, Europe, the United States, and other countries around the world, signifying a significant global reach and established distribution network.
A key aspect of Neuland Laboratories' business model is its provision of custom manufacturing solutions. This service allows pharmaceutical companies to outsource the production of specific APIs tailored to their unique needs and formulations. This approach offers flexibility and scalability to clients, enabling them to focus on research, development, and marketing while leveraging Neuland's manufacturing expertise and infrastructure.
Further enhancing its service portfolio, Neuland Laboratories offers specialized peptide synthesis services. Peptides are short chains of amino acids that play crucial roles in various biological processes, making them important components in a range of therapeutic applications. The company's proficiency in this area demonstrates a commitment to advanced pharmaceutical technologies and a capability to cater to the increasing demand for complex pharmaceutical molecules.
Established in 1984 and headquartered in Hyderabad, India, Neuland Laboratories has a long history in the pharmaceutical industry. This long-standing presence suggests experience in navigating regulatory landscapes, managing complex production processes, and building strong relationships with clients and regulatory bodies across different global markets. The company’s sustained operation and global footprint highlight its ability to adapt and thrive in a dynamic and competitive industry.
Questions investors ask about Neuland Laboratories Ltd (NEULANDLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Neuland Laboratories Ltd (NEULANDLAB)?
The current share price of Neuland Laboratories Ltd (NEULANDLAB) is ₹17,198. Today, the stock has gained by ₹225.00 (1.33%), trading in a range of ₹16,981 to ₹17,400. The stock opened at ₹17,122 with a trading volume of 35,209 shares.
02Is Neuland Laboratories Ltd stock a good investment for long-term?
Neuland Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹22,067.41 crores, P/E ratio of 60.67, ROE of 0.00%, and ROCE of 18.70%. The dividend yield stands at 0.20%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Neuland Laboratories Ltd stock?
The 52-week high price of Neuland Laboratories Ltd (NEULANDLAB) is ₹0, while the 52-week low is ₹0. Currently trading at ₹17,198, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Neuland Laboratories Ltd stock at the current price?
Whether to buy Neuland Laboratories Ltd stock at ₹17,198 depends on multiple factors. The stock is currently trading with a P/E ratio of 60.67 and P/B ratio of 11.77. Today's performance shows a gain of 1.33%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Neuland Laboratories Ltd and when is the next dividend?
Neuland Laboratories Ltd offers a dividend yield of 0.20%, which means for every ₹100 invested at the current price of ₹17,198, you can expect to receive approximately ₹0.20 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Neuland Laboratories Ltd?
Neuland Laboratories Ltd's key financial metrics include: P/E Ratio: 60.67, P/B Ratio: 11.77, ROE: 0.00%, ROCE: 18.70%, Dividend Yield: 0.20%, EPS: ₹283.45, Book Value: ₹1,460.92, and Debt-to-Equity: 16.07. The company's market cap stands at ₹22,067.41 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Neuland Laboratories Ltd stock performing today in the market?
Neuland Laboratories Ltd stock opened at ₹17,122 and is currently trading at ₹17,198, showing a gain of ₹225.00 (1.33%). The intraday high is ₹17,400 and low is ₹16,981. The trading volume stands at 35,209 shares, indicating moderate market participation today.
08What is the P/E ratio of Neuland Laboratories Ltd and what does it indicate?
Neuland Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 60.67, which means investors are willing to pay ₹60.67 for every ₹1 of earnings. With an EPS of ₹283.45, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Neuland Laboratories Ltd (NEULANDLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy